(Q24801695)

English

Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study)

scientific article

In more languages

Statements

scholarly article

0 references

Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study) (English)

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

I García-Cabeza

1

0 references

J C Gómez

2

0 references

J A Sacristán

3

0 references

E Edgell

4

0 references

M González de Chavez

5

0 references

language of work or name

0 references

publication date

2001

0 references

0 references

1

0 references

1

0 references

7

0 references

Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=65550

28 September 2017

The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=65550

28 September 2017

Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=65550

28 September 2017

Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=65550

28 September 2017

Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette's disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=65550

28 September 2017

A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=65550

28 September 2017

Haloperidol-induced dysphoria in patients with Tourette syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=65550

28 September 2017

Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=65550

28 September 2017

Dysphoric response to neuroleptic treatment in schizophrenia: its relationship to autonomic arousal and prognosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=65550

28 September 2017

Substance abuse in schizophrenia: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=65550

30 May 2018

A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=65550

30 May 2018

Rating of medication influences (ROMI) scale in schizophrenia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=65550

30 May 2018

Subjective response to antipsychotic drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=65550

30 May 2018

Response to antipsychotic medication: the doctor's and the consumer's view

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=65550

30 May 2018

Utility of the health belief model in examining medication compliance among psychiatric outpatients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=65550

30 May 2018

The importance of body experience for psychiatry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=65550

30 May 2018

Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=65550

30 May 2018

Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=65550

30 May 2018

Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors.

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-1-7

21 January 2018

Quality of life in schizophrenia: insight and subjective response to neuroleptics.

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-1-7

21 January 2018

Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group.

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-1-7

21 January 2018

Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life.

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-1-7

21 January 2018

Clinical management of clozapine patients in relation to efficacy and side-effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/11835695

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures

1 reference

https://pubmed.ncbi.nlm.nih.gov/11835695

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neuroleptic dysphoria

1 reference

https://pubmed.ncbi.nlm.nih.gov/11835695

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neuroleptic depression in schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/11835695

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early treatment events and prediction of response to neuroleptics in schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/11835695

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/11835695

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Kinetics and dynamics of response to haloperidol in acute schizophrenia—A longitudinal study of the therapeutic process

1 reference

https://pubmed.ncbi.nlm.nih.gov/11835695

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity

1 reference

https://pubmed.ncbi.nlm.nih.gov/11835695

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subjective response to neuroleptics in schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/11835695

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Psychological predictors of insight and compliance in psychotic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/11835695

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse

1 reference

https://pubmed.ncbi.nlm.nih.gov/11835695

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-244X-1-7

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Dimensions Publication ID

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24801695&oldid=2176941002"